Beyond a synthetic lethal pair: The atorvastatin-gefitinib combination as a testable model for cross-pillar therapy in colorectal cancer

Figure 1 Proposed AMP-activated protein kinase-sterol regulatory element-binding protein 1-centered model of the atorvastatin-gefitinib combination in colorectal cancer. Gefitinib is shown as an epidermal growth factor receptor tyrosine kinase inhibitor; phosphatidylinositol 3-kinase/protein kinase B- or phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta-related elements should be interpreted as downstream and context-dependent pathway components rather than direct pharmacological targets of gefitinib. EGFR: Epidermal growth factor receptor; PI3K: Phosphatidylinositol 3-kinase; AKT: Protein kinase B; AMPK: AMP-activated protein kinase; SREBP1: Sterol regulatory element-binding protein 1; HMGCR: 3-hydroxy-3-methylglutaryl-CoA reductase. Created with MedPeer (medpeer.cn).